Pear Therapeutics (PEAR) Tops Q1 EPS by 7c
Get Alerts PEAR Hot Sheet
Join SI Premium – FREE
Pear Therapeutics (NASDAQ: PEAR) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $2.4 million.
GUIDANCE:
Pear Therapeutics sees FY2022 revenue of $22 million.
For earnings history and earnings-related data on Pear Therapeutics (PEAR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- IDEX Corp. (IEX) Tops Q1 EPS by 13c ; Offers Guidance
- Texas Instruments (TXN) jumps as on earnings, revenue beat in fiscal Q1
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!